scholarly article | Q13442814 |
P50 | author | Meenhard Herlyn | Q16732421 |
Gordon B. Mills | Q28086262 | ||
Clemens Krepler | Q61529607 | ||
Robert H Mach | Q88117640 | ||
Patricia Brafford | Q125315151 | ||
Brandon Wenz | Q125342093 | ||
Katherine L Nathanson | Q37369859 | ||
P2093 | author name string | Mark Morgan | |
Neil Johnson | |||
Ronny Drapkin | |||
Yiling Lu | |||
Eric Brown | |||
Ying Zheng | |||
Fiona Simpkins | |||
Hyoung Kim | |||
George Cotsarelis | |||
Robert Soslow | |||
Mehran Makvandi | |||
Rugang Zhang | |||
Janos L Tanyi | |||
Erin George | |||
Xiaochen Zhang | |||
Stephanie Jean | |||
P2860 | cites work | Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization | Q23921272 |
Patient-derived tumour xenografts as models for oncology drug development | Q24604068 | ||
Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs | Q24610287 | ||
Emerging and Evolving Ovarian Cancer Animal Models | Q26783909 | ||
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts | Q26801063 | ||
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer | Q26801525 | ||
Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
Phenotypic instability of Saos-2 cells in long-term culture | Q28254879 | ||
ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays | Q28364520 | ||
Fast and accurate long-read alignment with Burrows-Wheeler transform | Q29547193 | ||
SIFT: Predicting amino acid changes that affect protein function | Q29547211 | ||
A framework for variation discovery and genotyping using next-generation DNA sequencing data | Q29547262 | ||
Cancer statistics, 2016 | Q29547383 | ||
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads | Q29617402 | ||
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
The microenvironment of the tumour-host interface | Q29620375 | ||
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer | Q30409503 | ||
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage | Q31160033 | ||
Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. | Q33607384 | ||
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. | Q33661151 | ||
Establishment of human tumor xenografts in immunodeficient mice | Q34003315 | ||
Patient-derived xenograft models in gynecologic malignancies | Q34141193 | ||
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations | Q34200152 | ||
Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner | Q34676703 | ||
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas | Q34998940 | ||
Cell cycle-related proteins p21 and bcl-2: markers of differentiation in the human fallopian tube | Q74081573 | ||
Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models | Q81120942 | ||
ATR prohibits replication catastrophe by preventing global exhaustion of RPA. | Q35051406 | ||
Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors | Q35105456 | ||
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines | Q35212640 | ||
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR | Q35640593 | ||
Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. | Q35736188 | ||
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. | Q35758403 | ||
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours | Q35759295 | ||
The promise and challenge of ovarian cancer models | Q35771750 | ||
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase | Q36075291 | ||
CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiation | Q36280773 | ||
It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. | Q36436803 | ||
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer | Q36568348 | ||
Chk1 and Claspin potentiate PCNA ubiquitination | Q36585485 | ||
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer | Q36586093 | ||
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. | Q36908567 | ||
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. | Q36941455 | ||
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo | Q36974565 | ||
Evaluating cell lines as tumour models by comparison of genomic profiles | Q37025950 | ||
ATR phosphorylates SMARCAL1 to prevent replication fork collapse | Q37064611 | ||
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling | Q37395388 | ||
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer | Q37438981 | ||
Advanced cytoreductive surgery: American perspective | Q37539178 | ||
Tumorgrafts as in vivo surrogates for women with ovarian cancer. | Q37626455 | ||
Epithelial ovarian cancer experimental models. | Q37708938 | ||
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? | Q38165720 | ||
Molecular Pathways: Targeting ATR in Cancer Therapy | Q38585436 | ||
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Q39282659 | ||
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. | Q39559122 | ||
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. | Q41316932 | ||
Characterization of a novel ATR-dependent, Chk1-independent, intra-S-phase checkpoint that suppresses initiation of replication in Xenopus | Q41846285 | ||
wANNOVAR: annotating genetic variants for personal genomes via the web. | Q42129589 | ||
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma | Q46390942 | ||
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. | Q52851743 | ||
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 | ||
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 1 | |
P921 | main subject | ovarian cancer | Q172341 |
xenograft | Q64148587 | ||
P304 | page(s) | e89760 | |
P577 | publication date | 2017-01-12 | |
P1433 | published in | JCI insight | Q27727187 |
P1476 | title | A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers | |
P478 | volume | 2 |
Q52430620 | A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. |
Q91820897 | An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer |
Q92476256 | Applications of patient-derived tumor xenograft models and tumor organoids |
Q92214119 | CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies |
Q55261818 | Chromosomal inversions as a hidden disease-modifying factor for somatic recombination phenotypes. |
Q97692537 | Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models |
Q64969004 | Current Status of Patient-Derived Ovarian Cancer Models. |
Q88875414 | Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma |
Q47107803 | Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines |
Q98777898 | Human-Derived Model Systems in Gynecological Cancer Research |
Q89471826 | MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC |
Q48124146 | Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells |
Q92126687 | Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer |
Q61812758 | Platinum Resistance in Ovarian Cancer: Role of DNA Repair |
Q52811875 | Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. |
Q90254910 | Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer |
Q91698737 | Xenograft and organoid model systems in cancer research |
Search more.